Study On The Expression Of ERCC1, RRM1 In Lung Adenocarcinoma, Squamous Cell Carcinoma And Its Relationship With Prognosis

BackgroundLung cancer is a common malignant tumor, the incidence and mortality of lung cancer increased gradually in recent years, in 2014 the whole world of new cases of lung cancer accounts for about 14% of all new malignant tumor, accounting for about 25% of all malignant tumor mortality, as one of the global cancer mortality rates are the highest in [1], and the non small cell lung cancer(non-small cell lung cancer, NSCLC) accounted for about to patients with 80%[2]. The new diagnosis of non-small cell lung cancer patients in about 25% can be operation treatment, although the postoperative adjuvant chemotherapy can improve the survival rate of 4% for 5 years, but there are still some patients relapse and metastasis, auxiliary chemotherapy effective or ineffective to screening postoperative become a medical problem. Therefore, more and more people believe that adjuvant therapy should be individualized treatment in determining the choice of adjuvant chemotherapy after resection of the guidance of molecular marker based on NSCLC patients. In recent years, the progress of study on molecular biology, molecular biological technology in-depth, more and cancer tumor markers were closely related to the development was found, individual treatment of tumor is more and more accepted by the people. Excision repair cross complementing gene 1(excision repair cross complementation 1, ERCCl), ribonucleotide reductase Ml(ribonucleotide reductase 1, RRMl) are often expressed in tumor tissues, its expression level may be related to the therapeutic efficacy of certain chemotherapy drugs related, so as the individual treatment of non small cell lung cancer in guiding treatment of tumor molecular marker commonly used. Research on a number of published confirmed, the level of ERCC1 expression correlated with platinum drug efficacy, high ERCC1 expression level may mean that the platinum primary drug resistance, low expression if ERCC1, is sensitive to platinum drugs; and the expression of RRM1 protein in tumor tissue of patients with sensitivity to gemcitabine related, if the expression of RRM1 protein is low, patients on gemcitabine drug sensitivity.Objectives Detection of non small cell lung cancer(non small cell lung cancer, NSCLC) patients, mainly for the patients with lung adenocarcinoma and squamous cell carcinoma, samples were operation excision specimens, detection of the corresponding specimens of ERCCl and protein expression level of RRMl, ERCC1, to investigate the expression of RRM1 protein in non small cell lung cancer after gemcitabine plus cisplatin(GP the relationship between) adjuvant chemotherapy prognosis, guide clinical individualized treatment.Material Follow up of 49 cases of clinical stage IIA-IIIA NSCLC patients accepted operation treatment, all patients had preoperative not accept any of the tumor therapy, all patients received postoperative chemotherapy 4 cycles. Immunohistochemical method was used to detect the expression of ERCC1, RRM1, and statistical analysis of patients with different clinical characteristics, pathological features, postoperative treatment, the expression of ERCCl/RRMl protein on progression free survival effect. Cox regression analysis to screen independent prognostic risk factors for Kaplan-Meier survival curves were compared, analysis of patients with progression free survival and overall survival time.Results:1、Results: expression of ERCC1 protein in 49 cases in the sample, 21 were positive; the expression of RRM1 protein in 30 cases results: positive. By immunohistochemical method in 49 cases of patients with tumor tissue samples of ERCC1 and RRM1 protein were determined, the results showed the expression of ERCC1, RRM1 protein levels in patients with the clinical and pathological parameters, such as: NSCLC in a sample of tissue pathological type, stage, lymph node metastasis status without.2、Overall survival status: postoperative patients the expression of ERCC1 group was better than that of ERCC1 expression, between the two groups, the median progression free survival and median overall survival has significant difference(15.2m VS 12.5m, P=0.038; 18.6m VS 16.8m, P=0.037).3、Overall survival status: postoperative patients the expression of RRM1 group was better than that of RRM1 expression, between the two groups, the median progression free survival and median overall survival difference was significant(14.6 P=0.048; 18.6 VS11.5 months, VS17.8 months, P=0.04).Conclusion:1、NSCLC samples of ERCC1 protein expression and pathological staging, lymph node metastasis and tissue pathological type of independent.2、NSCLC samples of RRM1 protein expression and pathological staging, lymph node metastasis and tissue pathological type of independent.3、Negative expression of ERCC1 NSCLC in patients with stage IIA-IIIA sensitive to platinum containing chemotherapy, survival advantages outweigh the high expression; while RRM1 expression in patients with NSCLC negative IIA-IIIA phase sensitive to the chemotherapy drug gemcitabine, survival advantages outweigh the high expression. Significant predictors of the expression level of ERCC1 and RRM1 may be prognostic survival as the evaluation of patients with application of GP scheme chemotherapy.